ES2062364T3 - Un metodo de preparacion de una composicion para el tratamiento despues de la exposicion de infeccion de rabia. - Google Patents

Un metodo de preparacion de una composicion para el tratamiento despues de la exposicion de infeccion de rabia.

Info

Publication number
ES2062364T3
ES2062364T3 ES90305844T ES90305844T ES2062364T3 ES 2062364 T3 ES2062364 T3 ES 2062364T3 ES 90305844 T ES90305844 T ES 90305844T ES 90305844 T ES90305844 T ES 90305844T ES 2062364 T3 ES2062364 T3 ES 2062364T3
Authority
ES
Spain
Prior art keywords
rabies
exposure
treatment
preparing
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90305844T
Other languages
English (en)
Inventor
Bernhard Dietzschold
Charles E Rupprecht
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wistar Institute of Anatomy and Biology
Original Assignee
Wistar Institute of Anatomy and Biology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wistar Institute of Anatomy and Biology filed Critical Wistar Institute of Anatomy and Biology
Application granted granted Critical
Publication of ES2062364T3 publication Critical patent/ES2062364T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

LA COMBINACION DE ANTICUERPOS MONOCLONALES ES UTIL PARA EL TRATAMIENTO, POR EXPOSICION POSTERIOR, DE MAMIFEROS CONTRA LOS VIRUS DE LA RABIA Y LOS RELACIONADOS CON LA RABIA. LA COMBINACION ES INMUNOREACTIVA FRENTE A LAS GLICOPROTEINAS Y NUCLEOPROTEINAS DEL VIRUS DE LA RABIA, Y ES REACTIVO, POR CRUZAMIENTO, CON LOS VIRUS RELACIONADOS CON LA RABIA DUVENHHAGE Y MOKOLA. EL VIRUS ESPECIFICO QUE NEUTRALIZA LA ACTIVIDAD ES SUPERIOR A LOS SUEROS HIPERINMUNES, ANTIRRABICOS EQUINOS O HUMANOS, Y SERA RECOMENDADO, DENTRO DE POCO, POR LA ORGANIZACION MUNDIAL DE LA SALUD COMO TERAPIA POR EXPOSICION POSTERIOR.
ES90305844T 1989-06-08 1990-05-30 Un metodo de preparacion de una composicion para el tratamiento despues de la exposicion de infeccion de rabia. Expired - Lifetime ES2062364T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36514389A 1989-06-08 1989-06-08

Publications (1)

Publication Number Publication Date
ES2062364T3 true ES2062364T3 (es) 1994-12-16

Family

ID=23437645

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90305844T Expired - Lifetime ES2062364T3 (es) 1989-06-08 1990-05-30 Un metodo de preparacion de una composicion para el tratamiento despues de la exposicion de infeccion de rabia.

Country Status (6)

Country Link
EP (1) EP0402029B1 (es)
AT (1) ATE99958T1 (es)
AU (1) AU626684B2 (es)
CA (1) CA2018508A1 (es)
DE (1) DE69005908T2 (es)
ES (1) ES2062364T3 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4006630A1 (de) * 1990-03-03 1991-09-12 Behringwerke Ag Humane monoklonale antikoerper gegen tollwutviren, ihre herstellung und verwendung
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
DK2314629T4 (da) 2002-07-18 2023-02-06 Merus Nv Rekombinant produktion af blandinger af antistoffer
WO2004106375A1 (en) 2003-05-30 2004-12-09 Merus Biopharmaceuticals B.V. I.O. Fab library for the preparation of anti vegf and anti rabies virus fabs
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
EP1737971B1 (en) 2004-01-20 2017-08-16 Merus N.V. Mixtures of binding proteins
EP2314620B1 (en) * 2004-05-27 2013-06-05 Crucell Holland B.V. Method of identifying binding molecules capable of neutralizing rabies virus
AU2011218689C1 (en) * 2004-05-27 2013-05-30 Crucell Holland B.V. Binding molecules capable of neutralizing rabies virus and uses thereof
CA2881717C (en) 2006-06-06 2018-06-12 Cecilia Anna Wilhelmina Geuijen Human binding molecules having killing activity against staphylococci and uses thereof
JP5410985B2 (ja) 2006-12-05 2014-02-05 クルセル ホランド ベー ヴェー 液体抗狂犬病抗体製剤
US8821879B2 (en) 2009-09-04 2014-09-02 Xoma Technology Ltd. Anti-botulism antibody coformulations
CA2814373C (en) 2010-10-19 2020-05-12 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Identification of antibodies specific for lyssaviruses and methods of their use
US9248181B2 (en) 2012-04-20 2016-02-02 Merus B.V. Methods and means for the production of Ig-like molecules
WO2017027805A1 (en) * 2015-08-13 2017-02-16 University Of Massachusetts Human antibodies against rabies and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4652629A (en) * 1985-07-03 1987-03-24 The Salk Institute For Biological Studies Synthetic peptide-based anti-rabies compositions and methods

Also Published As

Publication number Publication date
AU5686890A (en) 1990-12-13
DE69005908D1 (de) 1994-02-24
DE69005908T2 (de) 1994-04-28
CA2018508A1 (en) 1990-12-08
EP0402029A3 (en) 1991-02-13
EP0402029A2 (en) 1990-12-12
AU626684B2 (en) 1992-08-06
ATE99958T1 (de) 1994-01-15
EP0402029B1 (en) 1994-01-12

Similar Documents

Publication Publication Date Title
ES2062364T3 (es) Un metodo de preparacion de una composicion para el tratamiento despues de la exposicion de infeccion de rabia.
Dietzschold et al. Biological characterization of human monoclonal antibodies to rabies virus
Fekadu et al. Efficacy of rabies vaccines against Duvenhage virus isolated from European house bats (Eptesicus serotinus), classic rabies and rabies-related viruses
Schumacher et al. Use of mouse anti-rabies monoclonal antibodies in postexposure treatment of rabies.
BG98523A (en) Hla-limited cytotoxic t-lymphocytic (ctl) epitopes of the virus of hepatite b
DK0621898T3 (da) Kimæriske immunogener
DK0495008T3 (da) Vaccinekonjugat til behandling af fuglesygdomme
Harmon et al. Therapy of murine rabies after exposure: efficacy of polyriboinosinic-polyribocytidylic acid alone and in combination with three rabies vaccines
Pedersen Jr et al. Separation, isolation, and immunological studies of the structural proteins of Venezuelan equine encephalomyelitis virus
Kasempimolporn et al. Human immune response to rabies nucleocapsid and glycoprotein antigens
ATE96675T1 (de) Spezifische sekretions-exkretions-antigene von toxoplasma gondii, deren expressionsprodukte, verfahren zu deren herstellung und deren diagnostische und prophylaktische anwendungen.
DE69030099D1 (de) Verfahren zur herstellung von impfstoffen oder toxoiden
DE3853736D1 (de) Staupevirus-Impfstoff.
Mifune et al. A mouse model for the pathogenesis and postexposure prophylaxis of rabies
ATE132374T1 (de) Verhütung und behandlung einer retrovirenkrankheit
DE69109314D1 (de) Humaner monoklonaler Antikörper und diesen enthaltende Arzneimittelzusammensetzung zur Behandlung von Pseudomonasinfektionen.
Yoneda et al. Protection of mice from rabies by intranasal immunization with inactivated rabies virus
Vodopija Current issues in human rabies immunization
Crick The vaccination of man and other animals against rabies
Zanetti et al. Failure of protection induced by a Brazilian vaccine against Brazilian wild rabies viruses
DK0542895T3 (da) Krydsreaktiv influenza A immunisering
Kreil et al. Passive immunization reduces immunity that results from simultaneous active immunization against tick-borne encephalitis virus in a mouse model
DE68918127D1 (de) Peptidbehandlung von hartnäckigen Infektionskrankheiten.
ES2013665A6 (es) Procedimiento para preparar un anticuerpo monoclonal humano y metodo de uso.
ATE39055T1 (de) Verfahren zur immunisierung von schweinen gegen die aujeszky-krankheit.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 402029

Country of ref document: ES